Global “Plasma Fractionation Market” in terms of revenue was estimated to be worth $4.2 Bn in 2023 and is poised to reach $8.9 Bn by 2031, propelling at a CAGR of 10.1% from 2024 to 2031.
Global “Plasma Fractionation Market” in terms of revenue was estimated to be worth $4.2 Bn in 2023 and is poised to reach $8.9 Bn by 2031, propelling at a CAGR of 10.1% from 2024 to 2031.
Plasma fractionation process entails splitting plasma into proteins, further refined to produce finished pharmaceutical products. A variety of coagulation factors (such as prothrombin complex, factor VIII, factor IX, Von Willebrand factor, fibrinogen, and several others), immunoglobulins (IgGs), protease inhibitors (like alpha 1-antitrypsin and C1-inhibitor), anticoagulants (like antithrombin), and albumin are examples of plasma products. When considering the therapeutic function that these products play on a global scale, they must be extracted from human plasma by utilizing adequately controlled industrial procedures that ensure the highest possible quality, safety, and recovery.
Market Analysis:
The plasma fractionation market is estimated to expand at a compound annual growth rate. The major driver of the market’s growth is the growing prevalence of the age population, which results in more susceptibility to rare disorders that call for the usage of blood derivatives. Furthermore, the increased use of immunoglobulins in various fields of medicine around the world is anticipated to boost market growth. Another important driving factor is the rise in blood collection facilities worldwide.
Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/2140
Latest Drivers Restraint and Opportunities Market Snapshot:
Key Factors Influencing The Global Plasma Fractionation Market Are:
- With the rising prevalence of immune deficiencies, respiratory infections, hemophilia, and other blood-related disorders, the demand for these plasma-derived products continues to grow.
- Researchers are continually discovering new therapeutic indications for plasma-derived medicines driving the market.
- Increased awareness and improvised diagnostic services have led to more accurate identification and diagnosis of rare diseases, many of which require plasma-derived therapies for treatment. It drives up the demand for plasma fractionation.
The Following Are The Primary Obstacles To The Plasma Fractionation Market’s Expansion:
- The plasma fractionation process must adhere to stringent quality control to minimize the risk of contamination and transmission of infectious agents.
- High cost associated with plasma fractionation processes hinders market growth.
- Stringent regulatory requirements and complex approval processes for plasma-derived products can pose significant barriers to market entry.
Future Expansion Opportunities For The Global Plasma Fractionation Market Include:
- The growing demand for plasma-derived medications results in substantial growth opportunities for companies involved in plasma fractionation.
- As awareness of the importance of plasma donation increases, there is a potential for an expanded supply of plasma, which is the primary raw material for plasma fractionation.
- Continued advancements in plasma fractionation technologies can enhance the process’s efficiency and yield and, hence, propel market growth.
Key Industry Insights & Findings from the Report:
- The increasing incidence of immunological deficiencies, respiratory infections, and other illnesses has increased demand for plasma-derived therapies.
- Improved awareness and enhanced diagnostic services have resulted in more accurate detection and diagnosis of rare diseases, promoting market growth.
- North America dominated the market, accounting for a sizable portion of global revenue in 2023.
- A significant hurdle to industry expansion is the strict regulatory standards and complicated approval procedures for plasma-derived products.
List of Prominent Key Players in the Plasma Fractionation Market:
- CSL (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols, S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion S.P.A (Italy)
- LFB (France)
- ADMA Biologics (US)
- Sanquin (Netherlands)
- China Biologic Products Holdings Inc. (China)
- GC Pharma (Korea)
- Hualan Bioengineering Co., Ltd. (China)
- Japan Blood Products Organization (Japan)
- Emergent BioSolutions (US)
- Shanghai Raas Blood Products Co., Ltd. (China)
- Intas Pharmaceuticals Ltd. (India)
- Bharat Serum Vaccines Limited (India)
- SK Plasma (Korea)
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
- Kamada (Israel)
- Centurion Pharma (Istanbul)
- Prothya Biosolutions (Netherlands)
- PlasmaGen BioSciences Pvt. Ltd. (India)
- Virchow Biotech Private Limited (India)
- Fusion Healthcare (India)
- Hemarus Therapeutics Limited (India)
- Others
Recent Developments:
- In October 2022, Grifols launched a new albumin purification and filling plant in Dublin, Ireland, as part of its global manufacturing and supply hub. This expansion enhances the company’s capacity to produce albumin, a key component in plasma fractionation, contributing to meeting the growing demand in the plasma fractionation market.
- In September 2022, CSL Behring K.K. obtained approval from Japan’s Ministry of Health, Labour, and Welfare for Berinert S.C. Injection 2000. This lyophilized human C1-esterase inhibitor concentrate offers subcutaneous injection for preventing acute hereditary angioedema (HAE) attacks, displaying advancements in plasma derivatives for therapeutic applications in the plasma fractionation market
- In December 2023, G.C. Biopharma, a leading South Korea-based biopharmaceutical company, announced its plan to open the largest plasma fractionation plant at the Jababeka Industrial Estate in Indonesia. The plant is likely to boost the critical medical products sector in the country, with a maximum plasma fractionation capacity of 400,000 liters per annum. The facility is expected to commence production in 2027.
- In December 2023, PlasmaGen Biosciences, a biopharmaceutical firm focused on developing blood plasma-derived products for India and other emerging economies, announced an equity financing of US$27.0 Mn or INR 225 Cr. The move is projected to help the company expand its product portfolio at its world-class plasma manufacturing facility.
Plasma Fractionation Market Dynamics:
Market Drivers: Increasing Prevalence of Respiratory Infections
The escalating incidence of respiratory infections, compounded by factors such as aging populations and expanding healthcare infrastructure, is propelling the growth of the Plasma Fractionation Market. It is attributed to the rising demand for plasma-derived therapies, particularly immunoglobulins, vital in treating respiratory conditions like pneumonia and influenza. Moreover, advancements in fractionation technologies and the widening application spectrum of plasma-derived products further augment market expansion. With an increasing focus on healthcare and heightened awareness regarding infectious diseases, the Plasma Fractionation Market is poised for substantial growth, driven primarily by the escalating prevalence of respiratory infections.
Challenges: High Cost Associated With Plasma Fractionation Processes
Despite a diverse range of aesthetic applications, some limiting constraints are projected to hamper global market expansion over the forecast period. One of the key factors contributing to the global market’s slowing growth is the high cost of these items. : Plasma fractionation is a costly process involving sophisticated equipment and specialized facilities. High capital investment and operational expenses can limit the profitability of plasma fractionation facilities and discourage new entrants into the market.
North America Is Expected To Grow With Largest CAGR During The Forecast Period.
This market is predicted to be dominated by North America. North America is projected to dominate this market. The rise in respiratory diseases among North American individuals is attributed to the increased awareness of the numerous advantages of plasma therapies. Additionally, a boost in the consumption of immunoglobulin and the consistent ability to supply plasma owing to plasma collections and distribution all support the expansion of the regional market.
Segmentation of Plasma Fractionation Market-
By Type-
- Immune-Globulins
- Intravenous Immune-Globulins
- Subcutaneous Immune-Globulins
- Other Immune-Globulins
- Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrate
- Fibrinogen Concentrates
- Factor XIII
- Others
- Albumin
- Protease Inhibitors
- Other Plasma Products
By Application-
- Neurology
- Immunology
- Hematology
- Critical Care
- Pulmonology
- Hemato-Oncology
- Rheumatology
- Others
By End-Use
- Hospitals & Clinics
- Clinical Research Laboratories
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Talk with Experts Panel on the Plasma Fractionation Market Report @ https://calendly.com/insightaceanalytic/30min?month=2024-04
Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com